E³ - The Beauty of Basic Knowledge: Hybrid Imaging
E³ 24B - Hybrid imaging in oncology (part 2): a universe beyond FDG!
Lectures
1
Chairperson's introduction
05:00Clemens C. Cyran, München / DE
2
PSMA in prostate cancer management
12:00Alexander Walter Sauter, Baden / CH
3
Neuroendocrine tumours diagnostics and theranostics
12:00Wolfgang Fendler, Essen / DE
4
FAPI PET/CT: simply the new FDG?
12:00Frederik L Giesel, Düsseldorf / DE
5
Patient's perspective on prostate cancer screening
09:00Erik Briers, Hasselt / BE
6
Panel discussion: PSMA, DOTA, FAPI: theranostic rockstars on the rise?
10:00Panel discussion: PSMA, DOTA, FAPI: theranostic rockstars on the rise?
5 min
Chairperson's introduction
Clemens C. Cyran, München / Germany
12 min
PSMA in prostate cancer management
Alexander Walter Sauter, Baden / Switzerland
1. To know the appropriate indications for PSMA PET.
2. To recognise common pitfalls in Ga68 & F18 PSMA PET.
3. To learn how PSMA-PET can complement prostate MRI.
4. To understand how PSMA-PET is a gatekeeper for therapy planning.
2. To recognise common pitfalls in Ga68 & F18 PSMA PET.
3. To learn how PSMA-PET can complement prostate MRI.
4. To understand how PSMA-PET is a gatekeeper for therapy planning.
12 min
Neuroendocrine tumours diagnostics and theranostics
Wolfgang Fendler, Essen / Germany
1. To understanding the rationale for using FDG in addition to somatostatin receptor (SSR) PET in selected cases of NET.
2. To be aware of novel approaches to neuroendocrine tumours that lack SSR including tracers for CCK-2 and GLP-1.
3. To be able to discuss molecular imaging approaches for phaeochromocytoma and paraganglioma (PCPGL) that complement MRI and CT and when to use them.
4. To understand the importance of the universality and depth of target expression in determining suitability for radionuclide therapy and how to measure this.
2. To be aware of novel approaches to neuroendocrine tumours that lack SSR including tracers for CCK-2 and GLP-1.
3. To be able to discuss molecular imaging approaches for phaeochromocytoma and paraganglioma (PCPGL) that complement MRI and CT and when to use them.
4. To understand the importance of the universality and depth of target expression in determining suitability for radionuclide therapy and how to measure this.
12 min
FAPI PET/CT: simply the new FDG?
Frederik L Giesel, Heidelberg / Germany
1. To understand the pathophysiology behind FAPI PET.
2. To know about the major current indications of FAPI PET.
3. To discuss the potential of future FAPI applications in oncological imaging.
2. To know about the major current indications of FAPI PET.
3. To discuss the potential of future FAPI applications in oncological imaging.
9 min
Patient's perspective on prostate cancer screening
Erik Briers, Hasselt / Belgium
1. To learn that PSMA PET is to be included in metastatic prostate cancer diagnosis to better inform patients on their treatment options and prognosis.
2. To understand that patients are through their organisations and the internet well aware of new technological progress and that they want to benefit from these advances.
3. To understand that in rare prostate cancer types, like NET-PC, PSMA-PET can reveal the presence of the variant if compared with "traditional" imaging.
2. To understand that patients are through their organisations and the internet well aware of new technological progress and that they want to benefit from these advances.
3. To understand that in rare prostate cancer types, like NET-PC, PSMA-PET can reveal the presence of the variant if compared with "traditional" imaging.
10 min
Panel discussion: PSMA, DOTA, FAPI: theranostic rockstars on the rise?